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CLINICAL INVESTIGATION
Induction of heme oxygenase in toxic renal injury: A protective
role in cisplatin nephrotoxicity in the rat
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Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota and the Department of Molecular Genetics, Alton Ochsner
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Induction of heme oxygenase in toxic renal injury: A protective role in
cisplatin nephrotoxicity in the rat. Cellular content of heme is regulated
by heme oxygenase, the rate limiting enzyme in the degradation of heme.
Induction of heme oxygenase is a protective response in an in vivo model
of heme protein mediated renal injury, the glycerol model of acute renal
failure. In addition to heme, heme oxygenase is induced by diverse forms
of oxidative stress, the functional significance of which is currently
unknown. We examined whether heme oxygenase is induced, and the
functional significance of such induction, in two in vivo models of
oxidant-induced toxic nephropathy, namely, cisplatin and gentamicin
nephropathies; nephrotoxicity in these models is not dependent on the
delivery of a burden of heme proteins to the kidney as occurs in the
glycerol model. We demonstrate induction of heme oxygenase mRNA and
protein in the kidney as early as 6 and 12 hours after a single dose of
cisplatin (6 mg/kg iv.). Pretreatment with tin protoporphyrin, a competi-
tive inhibitor of heme oxygenase, led to higher serum creatinine values on
days 3 through 5 and lower inulin clearances on day 5; tin protoporphyrin
also exacerbated renal injury in this model. Renal hemodynamies studied
at day 2 after cisplatin demonstrate reduced renal blood flow rates,
increased renal vascular resistance and increased fractional excretion of
sodium in rats treated with tin protoporphyrin. Tin protoporphyrin alone
had no significant effect on serum creatinine and renal hemodynamics in
rats with intact, disease-free kidneys. We confirmed that tin protoporphy-
nfl prevented the increase in heme oxygenase activity induced by cisplatin.
Induction of heme oxygenase by cisplatin was associated with increased
kidney heme content and ferritin content. Induct ion of hense oxygenase,
as measured by mRNA and protein content, also occurred in gentamicin
nephropathy, though less than that observed in cisplatin nephropathy.
Inhibition of heme oxygenase did not influence sequential serum creati-
nine determinations in gentamicin nephropathy, thus indicating heteroge-
neity in the functional significance of induction of heme oxygenase in
oxidative stress. We conclude that the induction of heme oxygenase is a
protective response in toxic nephropathy, specifically, in cisplatin ne-
phropathy. Ferritin content is also increased by cisplatin, and by seques-
tering iron, may subserve a beneficial role in this model. Endogenous
heme, released from heme proteins, is potentially toxic and may contrib-
ute to cisplatin nephrotoxicity.
Heme oxygenase is the rate-limiting enzyme in the degradation
of heme [1—3]. This enzyme catalyzes the opening of the heme
ring and its conversion to biliverdin, a process that concomitantly
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releases iron from heme and yields carbon monoxide; subse-
quently biliverdin is converted to bilirubin [1—3]. Abundantly
present in tissues of the reticulo-endothelial system, heme oxyge-
nase enables these tissues to degrade hemoglobin released from
senescent red blood cells. The importance of this enzyme in the
degradation of heme is underscored not only by its copious
presence in these hemoglobin-degrading tissues but also by its
rapid and often fulminant induction in a wide variety of mamma-
lian cells exposed to heme [2, 4—7]. Such a response in cells will
eventually lower the intracellular levels of heme and thus safe-
guard against the potential toxicity of heme, a metabolite that can
attack and impair, in part through its prooxidant actions, a
number of subcellular targets [8]. That the induction of heme
oxygenase is a protective response in vivo against an inordinate
burden of heme was shown in vivo in studies involving the kidney,
an organ which expresses heme oxygenase poorly or not at all in
its intact, disease-free state [9]. The intramuscular injection of
hypertonic glycerol induces marked hemolysis and rhabdomyoly-
sis, thereby exposing the kidney to a large burden of heme
proteins and precipitating acute renal damage [9]. In this model
heme oxygenase is rapidly and prominently expressed in the
kidney, and inhibiting such activity by a specific competitive
inhibitor, tin protoporphyrin, worsens renal function while the
induction of heme oxygenase prior to the administration of
hypertonic glycerol protects against renal failure [9].
In addition to heme, a variety of other stimuli induce heme
oxygenase in vitro in mammalian cells, and these include hydrogen
peroxide, UV radiation, metals, endotoxin, cytokines and gluta-
thione depletion [2—7]. While the cellular mechanisms underlying
such induction of heme oxygenase are complex, one pathway
common to most of these stimuli is oxidative stress [2—7]. The
speculation has been offered that the expression of heme oxyge-
nase in these circumstances represents an adaptive response to
oxidative stress that mitigates the severity of oxidative damage [5,
6]. The mechanisms underlying the putative protective effects of
heme oxygenase in these circumstances are uncertain but involve
increased provision of bilirubin, an antioxidant metabolite capable
of effectively scavenging peroxy radicals and inhibiting lipid
peroxidation in vitro [10—11]. However, enhanced heme oxygen-
ase activity, in the absence of imposed heme or heme proteins,
may need not necessarily be beneficial, and in fact may have
harmful cellular actions: the liberation of iron provides a potential
catalyst to oxidative reactions while carbon monoxide in excessive
amounts may impair organelles such as the mitochondrion [12].
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Thus, in circumstances characterized by heme-independent oxi-
dative stress, contrary to current hypotheses, induction of heme
oxygenase could conceivably exacerbate cellular injury.
We attempt to resolve this issue by utilizing in vivo models of
toxic oxidant-induced nephropathy that are independent of the
imposition of a burden of heme proteins on the kidney. We
examined whether renal heme oxygenase is induced and the
functional significance of such induction in nephropathies in-
curred by cisplatin and gentamicin. The utility of these agents is
often limited by nephrotoxicity, and a considerable amount of
evidence substantiates the involvement of oxidative stress in the
pathogenesis of cisplatin and gentamicin nephropathies. Cisplatin
decreases kidney glutathione content and increases lipid peroxi-
dation [13—161; cisplatin interacts with DNA in a cell free system
and generates superoxide anion [17]; oxidant-scavenging enzymes
and assorted antioxidants protect against cisplatin-induced renal
injury [16, 18—20], while iron chelation with deferoxamine pre-
vents cisplatin-induced lipid peroxidation in rat kidney cortical
slices [21]. A similarly impressive body of work support the view
that gentamicin exerts nephrotoxic actions via oxidant pathways.
Gentamicin stimulates the production of hydrogen peroxide by
mitochondria in vitro [22] by the kidney in vivo [23], while the
severity of gentamicin-induced nephrotoxicity is attenuated by a
variety of antioxidants [24, 25]. Nephropathies induced by cispla-
tin or gentamicin thus provide in vivo oxidant states, independent
of heme protein delivery to the kidney, wherein the induction of
heme oxygenase can be examined and its functional signifi-
cance—be it a protector against or a perpetrator of renal inju-
ry—in such states elucidated.
Methods
Male Sprague-Dawley rats (225 to 275 g, Harlan, Madison, WI,
USA) were treated with a single intravenous dose of cisplatin, 6
mg/kg (1.5 mg/mi solution in sterile normal saline; Sigma Chem-
ical Co., St. Louis, MO, USA). With this dose, elevations in serum
creatinine were observed starting on day 3 and progressively
increased thereafter. In some protocols, tin protoporphyrin, 20
pmol/kg body wt, pH 7.5, (Porphyrin Products, Inc., Logan, UT,
USA), a specific competitive inhibitor of heme oxygenase, or
vehicle (normal saline) was administered subcutaneously, three
hours prior to cisplatin treatment. Identical doses of the inhibitor
were administered 8 and 24 hours after the first dose. Rats were
maintained on standard Purina rat chow (Purina, St. Louis, MO,
USA) and tap water ad libitum. Renal function was assessed by
serum creatinine values on a tail vein sample and measured by the
Jaffe reaction (Creatinine Analyzer II, Beckman Instruments,
Inc.). Kidneys were processed for histology, Western and North-
ern analyses.
Renal clearance studies
We performed renal clearance studies in this model at day 2
following cisplatin administration, prior to which animals received
tin protoporphyrin or vehicle. Studies were done under euvolemic
conditions, achieved with bovine serum albumin in normal saline,
in rats anesthetized with an intraperitoneal injection of 5-see-
butyl-5-ethyl-2-thiobarbituric acid (Inactin, 100 mg/kg body wt) as
previously described [26]. Arterial pressure was continuously
monitored by a femoral arterial catheter. Glomerular filtration
rate (GFR) and renal plasma flow rates for both kidneys were
determined by the clearances of inulin and para-aminohippurate,
respectively. Clearance data represented the mean of values
obtained in two consecutive clearance periods. Urinary and
plasma sodium, hematocrit and total protein concentration was
also determined. Renal blood flow, renal vascular resistance,
fractional excretion of sodium were calculated. To determine the
renal hemodynamic effects of the inhibitor, tin protoporphyrin, in
rats with normal kidneys, additional clearance studies were also
performed at day 2, in rats treated with similar doses of the
inhibitor or vehicle alone. To determine whether the elevation in
serum creatinine induced by tin protoporphyrin in rats with
cisplatin nephropathy was accompanied by lower GFRs, we also
performed inulin clearances at day 5, under euvolemic conditions
in rats with cisplatin nephropathy treated with tin protoporphyrin
or vehicle.
Morphometric studies
Histologic injury was quantified by morph ometty on day 5 after
cisplatin administration by methods described previously [26, 27].
Morphometric analyses were performed in kidneys fixed by
perfusion at mean arterial pressure of the rat with 1.25% glutar-
aldehyde in 0.1 M sodium phosphate buffer (pH 7.4, osmolality 300
mOsm/kg) followed by immersion in fixative for one hour. The
perfused kidney was sliced into coronal sections, and all slices
except the terminal slice lacking the corresponding right-side cut
surface were placed into cassettes, embedded in paraffin, and
sections were cut, 5 j.m thick. Analyses were performed in a
blinded fashion. Two histologic indices were selected that can be
readily and clearly identified: (i) intratubular casts and (ii) tubules
with frank necrosis as previously described. The volume densities
of tubular casts and necrotic tubules were then calculated.
Northern analysis
RNA extraction, Northern analysis and hybridization against
cDNA probes were performed as detailed by Rosenberg,
Chmielewski and Hostetter [28]. The cDNA probe for human
heme oxygenase was kindly provided by Dr. Rex Tyrrell and the
cDNA probe for H-ferritin and L-ferritin were obtained from Dr.
Hamish Munro. Autoradiograms were quantified by video densi-
tometry and expressed as corrected O.D. units by previously
described methods [29]. To standardize the Northern blots for
variability due to loading and transfer we performed video
densitometry, factoring the OD of the message for heme oxyge-
nase by the OD of the 18S rRNA on a negative of the ethidium
bromide stained nylon membrane. We employed this method in
preference to the use of housekeeping genes such as actin and
GAPDH for standardization of the Northern blots, since expres-
sion of these housekeeping genes per se may be altered by the
injurious insult [29].
Western analysis
Kidneys were harvested from rats 6, 12, 24 hours, two and five
days following cisplatin treatment (6 mg/kg i.v.) and on days 1, 3,
6, and 8 after the administration of gentamicin. Microsomal
membrane fractions were prepared as previously described [30]
and portions equivalent to 10 .tg of protein were electrophoresed
on a denaturing 12% polyacrylamide gel. The protein samples
were electrophoretically transferred to nitrocellulose membranes
and Western blot analysis was performed using a rabbit anti-rat
heme oxygenase-1 antibody (Stress Gen; Victoria, Canada) and a
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chemiluminescent detection system (Tropix, mc; Bedford, MA,
USA) according to the manufacturer's recommendation.
Heme oxygenase enzyme activity
Heme oxygenase activity was measured by bilirubin generation
in kidney microsomes as described previously [9, 31]. Kidney
microsomes were incubated with rat liver cytosol, a source of
biliruhin reductase (3 mg), hemin (20 .tM), glucose-6-phosphate
(2 mM), glucose-6-phosphate-dehydrogenase (0.2 U), and
NADPH (0.8 mM) for one hour at 37°C in the dark. The formed
bilirubin was extracted with chloroform and zOD 464 to 530 nm
was measured (extinction coefficient, 40 mM' cm1 for biliru-
bin) and enzyme activity expressed as pmol of bilirubin formed/60
mm/mg protein.
Kidney cytosolic ferritin
Kidney cytosolic ferritin content was determined using an
ELISA method as previously described [9, 31]. Kidney cytosol was
diluted 1:10000 and loaded into a 96-well ELISA plate overnight.
After incubation with 2% bovine serum albumin, the plates were
incubated with the primary antibody, anti-rat ferritin [9]. Anti-
rabbit IgG alkaline phosphatase conjugate was used as a second-
ary antibody. Rat ferritin was used as standard for the measure-
ment.
Heme content
For heme determination, the left kidney was perfused in situ
with phosphate buffered saline until the venous effluent was clear.
The kidney was then homogenized in 0,01 M Tris-HCI with 0.25 M
sucrose (1:5 wt/vol) and sonicated. An aliquot of the homogenate
was frozen at —70°C for determination of total kidney heme
content. To separate different subfractions the homogenate was
centrifuged first at 3000 g for 20 minutes at 4°C, followed by a
12,000 g centrifugation for 20 minutes at 4°C of the supernatant
and a final 105,000 g centrifugation of the 12,000 g supernatant for
one hour at 4°C. The resulting cellular subfractions consisting of
mitochondria, microsomes and cytosol were resuspended in phos-
phate buffer and aliquoted for heme measurement by the pyridine
hemochromogen method [32, 33]. Sodium dithionite (2 to 3 mg)
was used as a reducing agent and potassium ferricyanide (3 j.zi, 0.1
M) was used as an oxidizing agent in a final reaction mixture
consisting of about 1 mg protein of the sample. The absorbances
of the reduced sample were scanned between 570 and 520 nm
wavelength using the oxidized samples as blanks. From the
reduced minus oxidized spectrum of heme, the difference between
the a-maximum and the minimum was measured (557 and 541
nm, respectively), and using the extinction coefficient of 20.7
ml/mol cm, heme concentration was expressed as nmol of
heme/mg protein.
Total thiols, glutathione peroxidase and catalase activity
Kidneys were homogenized and determination of total thiols
was performed as previously described [341. Glutathione peroxi-
dase and catalase activity was determined in kidney cytosol by the
methods of Lawrence and Burk [35] and Aebi [36], respectively.
Gentamicin nephrotoxicity
Gentamicin (40 mg/mI; Gensia Laboratories, Ltd. San Diego,
CA, USA) was administered at a dose of 160 mg/kg body wt/day
daily for eight days, subcutaneously to male Sprague-Dawley rats
(225 to 275 g). Animals received three doses of tin protoporphyrin
or vehicle as above, the first dose prior to gentamicin. The
inhibitor was again administered at days 5 to 6 during the course
of gentamicin nephrotoxicity to maintain optimum inhibition of
heme oxygenase activity. Serum creatinine was monitored daily.
In a separate experiment, animals received gentamicin and kid-
neys were removed at sequential time points, one, three, six and
eight days during gentamicin treatment and processed for West-
ern and Northern analyses.
Ischemia-reperfusion induced renal injury
Ischemic renal failure was induced as previously described [37].
Under methohexital anesthesia (5 mg/100 g body wt by i.p.
injection), male Sprague-Dawley rats (225 to 275 g) underwent
right nephrectomy and occlusion of the left renal artery for 45
minutes using a non-traumatic vascular clamp. Serum creatinine
was determined 24 and 48 hours following the procedure.
Statistical analysis
Data are expressed as mean SEM. For comparisons involving
two groups, the unpaired t-test was used. For comparisons involv-
ing more than two groups ANOVA and the Student-Newman-
Keuls test were applied. All results are considered significant at P
<0.05.
Results
Induction of heme oxygenase in cisplatin nephropathy
Following the administration of a single intravenous dose of
cisplatin (6 mg/kg) significant elevations in serum creatinine
occurred at day 3 and increased thereafter. At day 5, mean serum
creatinine values in the cisplatin-treated and vehicle treated rats
were 2.3 0,1 and 0.3 0.01 mg/dI, respectively, N = 4 in each
group, P < 0.05. Cisplatin treated animals exhibited significant
weight loss (246.0 4.5 g and 213.3 7.6 g on days 1 and 5
respectively, P < 0.05) while the vehicle-treated rats gained
weight (248 2.1 g and 266.0 2.5 g on days I and 5, P < 0.05).
In this model of cisplatin nephropathy heme oxygenase mRNA
was induced in the kidney (Fig. 1). As shown in this Northern
aralysis, there was a time-dependent induction of heme oxygenase
mRNA. mRNA for heme oxygenase was induced as early as 6 and
12 hours following the administration of cisplatin and decreased
thereafter. The mean densitometric value, factored for the
amount of RNA transferred onto the nylon membrane, for each
group is as follows: (a) control, 0.9 0.8; (b) cisplatin one hour,
0.3 0.1; (c) 3 hours, 0.5 0.1; (d) 6 hours 41 7; (e) 12 hours,
40 3; (f) 24 hours, 19 7; (g) 2 days, 8 6; (h) 5 days, 6 2
corrected OD units. In addition to heme oxygenase mRNA, we
also confirmed by Western blot analysis, the presence of heme
oxygenase protein in the kidney. As shown in Figure 2, increased
expression of heme oxygenase occurred at six hours, with maximal
expression at 12 hours. Heme oxygenase protein was also detect-
able at 24 hours and two days, and was decreased by day 5. Thus,
these results indicate that heme oxygenase is induced in the
kidney and such induction occurs as early as six hours following
cisplatin administration.
We also explored whether induction of heme oxygenase was
accompanied by induction of other antioxidant enzymes in the
kidney such as glutathione peroxidase and catalase. Glutathione
peroxidase and catalase activities six hours after cisplatin were not
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Fig. 1. Heme oxygenase mRNA in rat kidney at 1, 3, and 6 hours (A), 12 and 24 hours (B), and 2 and 5 days (C), following cisplatin (6 mg/kg body wt,
iv.). Each lane represents RNA (20 jtg) from one kidney from an individual animal. Ethidium bromide stained nylon membrane with 18 s RNA for
corresponding autoradiogram on the left panel (D, E and F).
statistically different in the cisplatin and the vehicle groups
[glutathione peroxidase activity: 445.0 47.6 vs. 448.0 35.0
nmollminlmg protein; catalase activity: 0.33 0.01 vs. 0.34 0.01
k/mg protein, control (N = 5) versus cisplatin (N = 4) respec-
tively; P = NS]. Thus the induction of heme oxygenase was not
accompanied by induction of other antioxidant enzymes, such as
glutathione peroxidase and catalase.
Functional effect of inhibition of heme oxygenase in
cisplatin nephropathy
To examine the functional significance of induction of heme
oxygenase, we employed a specific competitive inhibitor, tin
protoporphyrin. Inhibition of heme oxygenase significantly wors-
ened renal function; by day 3 after administration of cisplatin,
serum creatinine was significantly higher in tin protoporphyrin
treated rats, and this difference progressively increased thereafter
(Fig. 3). While both groups had identical body wts on day 1 (256
3 vs. 257 4 g), cisplatin treated rats subjected to tin
protoporphyrin exhibited lower body wts by day 5 (201 7 vs. 219
6 g, P < 0.05). Gastrointestinal toxicity, a recognized effect of
cisplatin, was observed in both groups of rats. Tin protoporphyrin
treatment in rats with cisplatin nephropathy led to similar hema-
tocrits on days 1 and 2, significantly higher values on days 3 (55
1 vs. 49 1%) and day 4 (53 1 vs. 49 1%) and numerically
lower values on day 5 (46 1 vs. 48 1%).
We confirmed that the administration of tin protoporphyrin
resulted in inhibition of heme oxygenase enzyme activity in the
kidney. These studies were undertaken at day 3 after cisplatin. As
shown in Figure 4, cisplatin induced a fivefold increase in heme
oxygenase activity which was totally prevented by tin protopor-
phyrin.
We also studied the effect of tin protoporphyrin on renal
function in rats with intact, disease-free kidneys. Tin protopor-
phyrin did not impair renal function in rats with disease-free
kidneys: sequential serum creatinine values were unchanged from
control values determined up to five days after the administration
of tin protoporphyrin or vehicle alone (data not shown). To
examine further the specificity of our observations in cisplatin
induced nephropathy, and to exclude any possible nonspecific
effects that may occur indiscriminately in the injured kidney, we
studied the effects of inhibition of heme oxygenase in an ischemia-
reperfusion model, one in which heme oxygenase is not induced
[381. Tin protoporphyrin had no effect on renal function as
assessed by serum creatinine on day 1 and 2 in this model
(vehicle-treated vs. tin protoporphyrin- treated: baseline, 0.31
0.01 vs. 0.32 0.01; day 1, 0.81 0.14 vs. 0.85 0.12; day 2, 0.68
0.08 vs. 0.60 0.08 mg/dl; N = 6 in each group, P NS). Thus,
the exacerbatory effect of tin protoporphyrin in cisplatin nephrop-
athy was not due to the effect of tin protoporphyrin per se but
reflects the effect of the inhibitor superimposed on cisplatin-
mediated renal injury.
We performed renal clearance studies in rats with cisplatin
nephropathy subjected to tin protoporphyrin or vehicle. These
studies were performed at day 2 following cisplatin, a time point
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cally lower in animals pretreated with tin protoporphyrin com-
pared to those pretreated with vehicle (0.90 0.09 vs. 1.02 0.09
mi/rn in, N = 14 in each group, P = NS). Mean arterial pressures
during clearances were comparable in the two groups (cispiatin
with tin protoporphyrin, 97 3 and cisplatin with vehicle, 94 1
mm Hg, P NS). However, renal blood flow was significantly
reduced in cisplatin treated rats subjected to concomitant treat-
ment with tin protoporphyrin (Fig. 5); pretreatment with tin
protoporphyrin markedly and significantly reduced renal blood
flow rates to a value approximately 60% of the renal blood flow in
cisplatin treated rats administered vehicle only. Calculated renal
vascular resistances doubled following prior administration of tin
protoporphyrin in this model (cisplatin with tin protoporphyrin vs.
cisplatin with vehicle: 22.7 4.4 and 11.0 1.5 mm Hg . mm/mI,
respectively, P < 0.02). Renal clearance studies were also per-
formed in a separate experiment in rats with normal kidneys
treated with tin protoporphyrin or vehicle alone (N = 4 in each
group); tin protoporphyrin did not significantly alter glomerular
filtration rate (GFR, 2.31 0.24 vs. 2.67 0.18 ml/min), mean
arterial pressure (MAP, 113 8 vs. ill 4 mm Hg) and renal
blood flow rates (RBF, 20.0 2.6 vs. 22.9 1.6 ml/rnin) in rats
with intact, disease free kidneys. Thus, the differences we ob-
served with tin protoporphyrin in cisplatin nephropathy cannot he
ascribed to the effects of tin protoporphyrin per se on renal
function.
Fractional excretion of sodium (FENd) was employed to assess
tubular function. FENa was significantly higher in rats with
cisplatin nephropathy pretreated with the inhibitor, tin protopor-
phyrin, attaining an elevenfold increment (cisplatin with vehicle,
0.0010 0.0002; cisplatin with tin protoporphyrin, 0.011 + 0,004,
P < 0.01). Thus inhibition of heme oxygenase worsens tubular
dysfunction as measured by this index. It should be pointed out
that the treatment of rats with normal kidneys with tin protopor-
phyrin as compared to vehicle led to a nonsignificant numerical
fourfold increase in FENa (0.004 0.004 and 0.001 0.0002,
respectively, N = 4 in each group, P NS). Thus, the elevenfold
significant increase in FENa in cisplatin treated rats subjected to
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Fig. 2. Western blot demonstrating induction of heme oxygenase (HO-i)
protein in rat kidney .ciz hours (lane 2), 12 hours (lane 3), 24 hours (lane 4),
Iwo days (lane 5) and five days (lane 6) following cisplatin treatment. Lane
1 represents a control animal. The migration and size (kDa) of the
molecular weight standards are indicated.
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Fig. 3. Functional significance of induction of heme oxygenase activity in
cisplatin nephrotoxicity: Effect of inhibition of heme oxygenase with tin
protopoiphyrin. •, cisplatin with vehicle (N 6); , cisplatin with tin
protoporphyrin (N 7) ' P < 0.001.
at which we did not observe any significant difference in serum
creatinine values. Body weights (218 2 vs. 219 3 g), basal
hematocrit (44 I vs. 45 1%) and basal total plasma proteins
(6.1 0.1 vs. 6.0 0.1 g/dl) were not significantly different
between these two groups. GFR was numerically but not statisti-
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Table 1. Renal clearance data in rats treated with cisplatin (6 mg/kg
iv.) with vehicle and cisplatin with tin protoporphyrin, studied at day 5
Cisplatin +
vehicle
(N=6)
Cisplatin + tin
protoporphyrin(N=8)
Body weight g 211 4 204 3
Total plasma proteins g/dl 6.0 0.1 6.0 0.1
Hematocrit % 51 1 49 I
Basal MAP mm Hg 101 3 93 2
MAP during clearance
mmHg 116±3 103±3°
GFR
pi/min/l00 g body wt 76 21 30 5°
GFR p1/mm 162±51 61 11"
Values expressed as mean SEM. Abbreviation is MAP, mean arterial
pressure.aP < 0.05, cisplatin with vehicle vs. cisplatin with tin protoporphyrin
(day 5)
tin protoporphyrin pretreatment cannot be ascribed to the effects
of tin protoporphyrin per se.
We also determined GFR by inulin clearance under euvolemic
conditions five days after the administration of cisplatin in rats
that were treated with tin protoporphyrin or vehicle. This was to
assess whether the higher serum creatinine values observed in rats
with cisplatin nephropathy treated with tin protoporphyrin re-
flected lower GFR, These data are summarized in Table 1. In this
study, body weights in these two groups were not significantly
different, nor were there any significant differences in hematocrit,
total plasma protein concentrations or mean arterial pressure in
the basal state prior to the commencement of the clearance
studies. While marked reductions occurred in both groups, GFRs
measured by inulin clearance under euvolemic conditions and
expressed either in absolute values or per unit body wt were
significantly lower in rats with cisplatin nephropathy concomi-
tantly treated with tin protoporphyrin.
Structural effect of inhibition of heme oxygenase in
cisplatin nephrotoxiciiy
Exacerbation of renal function was accompanied by worsening
of structural injury as demonstrated by morphometric analysis
performed on day 5 after cisplatin treatment. A higher volume
density of tubular necrosis and casts occurred in the animals
pretreated with tin protoporphyrin (Fig. 6). Thus inhibition of
heme oxygenase worsens structural derangements in this model.
Effect of inhibition of heme oxygenase on ferritin content in
cisplatin nephropathy
Prior studies from our laboratory have demonstrated that the
induction of heme oxygenase is linked to increased ferritin
content [91. Such increased ferritin content in states characterized
by increased amounts of heme or oxidants may provide a storage
site for iron released from heme proteins as a consequence of
heme oxygenase activity. We therefore determined ferritin con-
tent in kidneys subjected to cisplatin nephrotoxicity and treated
concomitantly with tin protoporphyrin or vehicle.
A twofold increase in cytosolic ferritin occurred in kidneys
exposed to cisplatin and vehicle. Such increase in ferritin in
response to cisplatin was unabated when the activity of heme
oxygenase was inhibited by tin protoporphyrin (Fig. 7). Thus, the
exacerbatory effects of tin protoporphyrin was not due to the
suppression of ferritin synthesis elicited by cisplatin in the kidney.
This increase in ferritin content in response to cisplatin was not
accompanied by enhanced expression of H- or L-ferritin mRNA
(data not shown), thus suggesting that this was due to post-
transcriptional mechanisms, as has been noted for other instances
where ferritin is induced by iron or heme.
Alterations in heme content and total thiol content in
cisplatin nephropathy
To determine the mechanisms that may account for the induc-
tion of heme oxygenase by cisplatin, we examined two potential
pathways that are recognized as inducers of heme oxygenase:
increased tissue content of free heme and thiol depletion. The
purpose of measuring these parameters at six hours after cisplatin
was to determine if significant alterations in heme or thiol content
occurred at a time period when heme oxygenase induction was
observed. Heme was determined in total kidney homogenate and
assorted subcellular fractions. The results are summarized in
Table 2. Free heme content increased with cisplatin administra-
tion in total kidney and cytosolic fractions, and tended to increase
in mitochondria, whereas microsomal heme content was not
significantly different. The results of total thiols (predominantly
comprising of glutathione) in the kidneys of rats treated with
cisplatin (6 mg/kg) revealed that total thiols in the kidney were not
decreased, but were significantly higher in cisplatin treated rats
compared to the vehicle treated rats (30.6 1.2 vs. 39.4 0.9
nmol/mg protein, P < 0.05). Thus, it is unlikely that alterations in
kidney thiol content served as a stimulus for heme oxygenase
whereas it is possible that increased amounts of free heme may
induce heme oxygenase in the cisplatin treated kidneys.
A
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Fig. 5. Effect of tin protoporphyrin on renal
hemodynamics in cisplatin nephrotoxicity: effects
on (A) renal blood flow (P < 0.03) and (B) renal
vascular resistance (P < 0.02) on day 2. Symbols
are: (U) cisplatin with vehicle; () cisplatin
with tin protoporphyrin; N = 14 in each group.N=14 N=14
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Fig. 7. Kidney cytosolic ferritin content at day 2 after cisplatin (6 mg/kg).
Symbols are: (LI) control (N = 6); (U) cisplatin with vehicle (N = 9); ()
cisplatin with tin protoporphyrin (N = 8). * P = NS, cisplatin with vehicle
versus cisplatin with tin protoporphyrin; 1 P < 0.05, control versus
cisplatin with vehicle or cisplatin with tin protoporphyrin.
Control (N = 5) Cisplatin (N = 4) P value
Total kidney 0.49 0.01 0.55 0.01 0.008
Cytosol 0.27 0.01 0.47 0.03 0.0004
Mitochondria 0.72 0.01 0.77 0.03 0.06
Microsomes 0.84 0.05 0.95 0.04 0.11
Induction of heme oxygenase in gentamicin nephropathy and effect
of inhibiting heme oxygenase
To test the specificity of our observations in cisplatin nephro-
toxicity, we studied another model of toxic nephropathy, genta-
micin induced nephrotoxicity. Previous studies have demonstrated
that oxygen-derived free radicals play a significant role in this
model [23—25]. Induction of heme oxygenase mRNA and protein
occurred at day 3 in this model of gentamicin nephrotoxicity (Fig.
8 A, B). The mean (of duplicates) densitometric value, factored
for the amount of RNA transferred onto the nylon membrane, for
each time period is as follows: (a) control, 0.9 0.2; (b)
gentamicin one day, 1.43 0.2; (c) 3 days, 10.5 2; (d) 6 days, 3
0.4; (e) 8 days, 1.3 0.8 corrected OD units. The nature of the
=45 kD polypeptide seen in Figure 8B, that reacts with the heme
oxygenase antibody is unclear. This protein is present abundantly
in several cell lines, but the expression is not inducible by agents
that stimulate heme oxygenase synthesis. Sequential assessment of
renal function by serum creatinine measurement, after pretreat-
ment with the heme oxygenase inhibitor, tin protoporphyrin,
failed to demonstrate any significant functional effect of tin
protoporphyrin in this model (Table 3). Thus, inhibition of heme
oxygenase in the gentamicin model, one in which heme oxygenase
is induced, did not impair renal function, at least as measured by
serum creatinine determinations.
Discussion
Alterations in cellular redox and/or increases in cellular heme
content are features common to stimuli that induce heme oxyge-
nase [2—7]. While the functional consequences of the induction of
heme oxygenase in heme-dependent oxidant stress reside in the
ability of this enzyme to reduce intracellular levels of heme, the
functional significance of its induction in heme-independent oxi-
dant stress is puzzling. To attempt to elucidate the role of heme in
this latter form of oxidative stress, we utilized a toxic nephropathy
model, cisplatin nephropathy, one in which multiple lines of
evidence attest to the involvement of oxidative stress in the
pathogenesis of renal injury [14—17]. This study demonstrates that
heme oxygenase is induced in the kidney following the adminis-
tration of cisplatin. Such induction is characterized by increased
amounts of heme oxygenase mRNA and protein, each detectable
as early as six hours after the administration of cisplatin, and
associated with increased enzyme activity. Inhibition of this
enzyme by a specific competitive inhibitor, tin protoporphyrin,
worsened the course of cisplatin nephropathy as assessed by
functional and structural indices. Renal hemodynamic studies
performed at day 2—a time-point at which significant elevations
in serum creatinine had not yet occurred in tin protoporphyrin-
treated rats—revealed a hemodynamic effect of tin protoporphy-
nfl in rats with cisplatin nephropathy. In this latter group, renal
vascular resistance was increased and renal blood flow rates were
decreased; additionally, tin protoporphyrin worsened tubular
function as reflected by higher fractional excretion of sodium. Tin
protoporphyrin did not adversely affect renal function in states in
which heme oxygenase is not induced, either in rats with intact,
disease-free kidneys, or in rats with postischemic renal disease.
Therefore, tin protoporphyrin does not indiscriminately and
nonspecifically worsen renal function. We confirmed that tin
protoporphyrin effectively inhibited heme oxygenase activity, and
indeed prevented the fivefold increase in enzyme activity induced
by cisplatin. In aggregate these data provide the first evidence that
the induction of heme oxygenase in vivo in a model of oxidant-
induced, toxic nephropathy subserves a protective role.
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Fig. 6. Morphometric indices in cisplatin
nephrotoxicity with and without tin protoporphyrin
pretreatment, five days after the administration of
cisplatin. (A) Necrotic tubules (P < 0.001). (B)
Tubular casts (P < 0.01). Symbols are: (U)
cisplatin with vehicle (N = 6); () cisplatin
with tin protoporphyrin (N = 7).
-r
Table 2. 1-leme content in the kidney and subcellular fractions, 6 hours
after administration of cisplatin (6 mg/kg)
Values expressed as mean SEM, nmol/mg protein for all fractions.
7 8 910
1 2 3 4 5 6
1 234 56
HO -
protein
Fig. 8. Induction of heme oxygenase mRNA (A)
and protein (B) in gentamicin nephrotoxicity. (A)
Northern analysis demonstrating induction of
heme oxygenase mRNA in the kidney: vehicle-
treated (lanes 1, 2), gentamicin treated kidney
day 1 (lanes 3, 4), day 3 (lanes 5, 6), day 6
(lanes 7, 8), and day 8 (lanes 9, 10). Each lane
represents RNA (20 rg) from one kidney from
an individual animal. The ethidium bromide
stained nylon membrane for the above
autoradiogram is shown in the lower panel. (B)
Western analysis demonstrating induction of
heme oxygenase (HO-i) protein in the rat
kidney at day 1 (lane 2), day 3 (lane 3), day 6
(lane 4), day 8 (lane 5) in gentamicin
nephrotoxicity. Lane 6 represents a cisplatin
treated kidney at 24 hours. Lane i represents a
control animal. Heme oxygenase migrates as a
3i kD size protein. The migration and size
(kD) of the molecular weight standards are
indicated.
Table 3. Effect of tin protoporphyrin on renal function following daily
gentamicin (160 mg/kg body wt)
Control
(N = 4)
Vehicle + gentamicin
(N = 6)
Tin protoporphyrin
+ gentamicin (N = 7)
Day i 0.3 0.05 0.4 0.06 0.5 0.03
Day 3 0.3 0.00 0.4 0.04 0.4 0.03
DayS 0.3 0.00 0.9 0.i7 1.1 0.08
Day 7 0.3 0.01 2.1 0.31 2.5 0.i7
To explore potential mechanisms accounting for the induction
of heme oxygenase in cisplatin nephropathy, we focused on the
substrate for heme oxygenase, namely, heme. Thiol depletion,
another potent stimulus for the induction of heme oxygenase, was
not present in the kidney six hours after the administration of
cisplatin, and thus cannot be incriminated as the trigger for such
induction. Our results demonstrate that six hours after cisplatin,
total kidney and cytosolic heme contents were higher in cisplatin-
treated animals compared to controls. We suggest that such
increments in heme may drive expression of heme oxygenase.
Measurements of heme and thiol contents at earlier time points
would be of interest since one would anticipate that alterations in
these parameters may antedate the induction of heme oxygenase.
While we did not examine the mechanism accounting for increase
heme content in the kidney, we speculate that such increased
amounts of heme may originate from destabilized intracellular
heme proteins. Heme-containing proteins are ubiquitous in cells:
besides hemoglobin and myoglobin, the heme prosthetic group is
found in such diverse proteins as mitochondrial and microsomal
cytochromes, nitric oxide synthase, prostaglandin endoperoxide
synthase, catalase, peroxidases, certain oxygenases, respiratory
burst oxidase and pyrrolases [3, 5]. Oxidative stress may destabi-
lize heme proteins [39], and as the union of the heme and protein
moieties is weakened, the release of heme from its binding protein
may occur. We speculate that oxidant stress resulting from
cisplatin may unfetter the heme prosthetic group from its allied
protein. The heme prosthetic group, either directly or via the
effects of its released iron, can damage a number of cellular
targets including lipid bilayers, cytoskeleton, mitochondria, enzy-
matic proteins, the antioxidant reserve and the nucleus [8, 40].
Interestingly, many of these targets are also recognized as sites
that are injured in cisplatin nephropathy [14—17, 41, 421. Induc-
tion of heme oxygenase following the administration of cisplatin
thus represents a response that restrains the increment in cellular
heme content that would otherwise occur. We wish to point out
that while prior studies demonstrate increased renal content of
heme, such changes in heme were observed at a delayed time-
point, that is, seven days after the administration of cisplatin, a
point at which the kidney is profoundly damaged [43J. Such
increments in heme at this much later time point are attributed to
increased heme synthesis effected by increased ferrochelatase
activity. Our studies uncover increments in heme as early as six
hours after the administration of cisplatin, a timepoint prior to the
occurrence of overt renal injury, and one that is accompanied by
induction of heme oxygenase.
In addition to the induction of heme oxygenase, the adminis-
tration of cisplatin leads to increased ferritin content of the
kidney. In previous studies increased ferritin content accompa-
nied the induction of heme oxygenase in an in vivo model of heme
protein-mediated renal injury [9]. By chelating iron released as a
consequence of increased heme oxygenase activity, such increased
ferritin content likely subserves a protective role [9, 31]. There-
fore, the extent to which catalytic "free" iron contributes to renal
Control id 3d 6d 8d
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Serum creatinine (mgldl) values expressed as mean SEM. P values are
not significant.
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injury induced by cisplatin, increased amounts of ferritin, which is
linked to increased heme oxygenase activity, may provide an
additional renal response that serves to protect the kidney in
cisplatin nephropathy. Other mechanisms by which induction of
heme oxygenase may offer protection include increased genera-
tion of bilirubin, a metabolite with potent antioxidant capabilities
in vitro [10, 111. Our studies raise the possibility that effects of
enhanced heme oxygenase activity on renal hemodynamics may
also be beneficial in this model. In rats with cisplatin nephropathy
the administration of tin protoporphyrin decreased renal blood
flow and increased calculated renal vascular resistances at a
relatively early timepoint in the course of progressive renal
failure, and prior to the emergence of differences in GFR as
reflected by serum creatinine determinations. Such augmentation
in renal vasoconstriction in cisplatin nephropathy, incurred by
ablating the increase in heme oxygenase activity that normally
occurs, indicates that the maintenance of renal blood flow is
dependent on enhanced heme oxygenase activity. In this regard
we offer two speculations. Firstly, increased heme oxygenase
activity generates carbon monoxide, a metabolite with potent
vasodilatory effects mediated in part through cGMP [44, 45]; in
addition, carbon monoxide is also recognized as an important
intracellular signaling molecule in neural tissues [461. Generation
of this vasodilator in increased amounts by enhanced heme
oxygenase activity in the cisplatin treated kidney may serve to
dilate the renal vasculature. Secondly, increased intracellular
heme, which we detect in cisplatin nephropathy, may contribute to
renal vasoconstriction since heme is recognized as a binding site
for nitric oxide [47]. Basal renal vasodilatation is critically depen-
dent on nitric oxide and quenching of nitric oxide, as occurs in
assorted disease states, contributes to renal vasoconstriction [48—
50]. We speculate that by degrading such increased amounts of
intracellular heme, and thus removing a sump for nitric oxide,
enhanced heme oxygenase activity may thus maintain renal blood
flow.
We also selected for examination another model of toxic
nephropathy, gentamicin nephropathy, one in which enhanced
generation of reactive oxygen species is incriminated in the
pathogenesis of renal injury. This latter model of renal injury is
characterized by increased generation of hydrogen peroxide [22,
231 and assorted scavengers of reactive oxygen species reduce
structural and functional renal injury in this model [24, 25].We
provide the first demonstration in this model that heme oxygenase
is induced. However, in contrast to effects observed in the
cisplatin model, we found no evidence for a functional effect
accruing from inhibition of heme oxygenase activity. These find-
ings are instructive in that they underscore the heterogeneous
effects resulting from the induction of heme oxygenase in diseased
states. In settings such as gentamicin nephropathy wherein the
induction of heme oxygenase leaves the kidney subjected to
oxidative stress unaided, it is likely that the induction of heme
oxygenase fails to fulfill the critical requirements of an effective
antioxidant strategy [7], that is, the provision of adequate amounts
of an appropriate scavenger either at cellular loci where oxidants
are generated or at those vulnerable and vital cellular targets that
suffer the brunt of oxidative attack. Thus in states of tissue injury
wherein it is induced, heme oxygenase can be a protectant or in
others a seemingly disinterested bystander [40]. Such divergent
functional effects arising from the induction of heme oxygenase
urge caution in inferring the functional significance of its induc-
tion in one given setting based on conclusions derived from
another.
In conclusion, this study provides the first demonstration that a
model of oxidant-induced toxic nephropathy and one not depen-
dent on the delivery of heme proteins to the kidney—in cisplatin
nephropathy—the induction of heme oxygenase affords protective
effects. In this model increased amounts of endogenous heme is
detected in the kidney, and such heme may contribute to the
induction of heme oxygenase and the injury that ensues. Induction
of heme oxygenase also occurs in another oxidant-driven, toxic
nephropathy model, gentamicin nephropathy, but in this latter
model, inhibiting its activity fails to exacerbate the course of renal
insufficiency.
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